Revenue - AVROBIO Inc (NASDAQ:TECX) - Alpha Spread

AVROBIO Inc
NASDAQ:TECX

Watchlist Manager
AVROBIO Inc Logo
AVROBIO Inc
NASDAQ:TECX
Watchlist
Price: 19 USD 1.88% Market Closed
Market Cap: 279.9m USD
Have any thoughts about
AVROBIO Inc?
Write Note

AVROBIO Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AVROBIO Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
AVROBIO Inc
NASDAQ:TECX
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$55B
CAGR 3-Years
1%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.8B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Revenue
$30.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.3B
CAGR 3-Years
16%
CAGR 5-Years
25%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.5B
CAGR 3-Years
3%
CAGR 5-Years
16%
CAGR 10-Years
18%

See Also

What is AVROBIO Inc's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2023, AVROBIO Inc's Revenue amounts to 0 USD.

Back to Top